Quanterix Announces Receipt of Expected Notice From Nasdaq
Quanterix Announces Receipt of Expected Notice From Nasdaq
The Company is continuing to work expeditiously to complete the filing of the Form 10-Q and remains on track to complete the restatement and all required filings by the end of 2024.BILLERICA, Mass.--(BUSINESS WIRE)--Nov. 22, 2024--Quanterix Corporation (NASDAQ: QTRX) today announced that it received a notice (the "Notice") on November 21, 2024 from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the "Form 10-Q"), it is no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission (the "SEC").
比勒裏卡，馬薩諸塞州.--(商業新聞)--2024年11月22日--Quanterix公司（納斯達克：QTRX）今天宣佈，2024年11月21日收到納斯達克證券市場有限責任公司（"納斯達克"）的通知（"通知"），指出由於本公司尚未提交截至2024年9月30日的季度報告10-Q表（"10-Q表"），因此不再符合納斯達克上市規則5250(c)(1)（"規則"），該規則要求上市公司及時向證券交易委員會（"SEC"）提交所有必需的定期基本報表。
The Notice has no immediate effect on the listing or trading of the Company's common stock on Nasdaq. Under Nasdaq rules, the Company has 60 calendar days from receipt of the Notice, or until January 20, 2025, to submit a plan to regain compliance with the Rule.
該通知對本公司普通股在納斯達克的上市或交易沒有立即影響。根據納斯達克的規定，本公司在收到通知後有60個日歷天的時間，即截至2025年1月20日，提交計劃以重新獲得規則的合規性。
On November 12, 2024, the Company previously announced that it would be delayed in filing the Form 10-Q due to the need to restate the Company's audited consolidated financial statements as of December 31, 2023 and 2022 and for each of the three years in the period ended December 31, 2023, and its unaudited consolidated financial statements for the quarterly and year-to-date (as applicable) periods ended March 31, 2022, June 30, 2022, September 30, 2022, March 31, 2023, June 30, 2023, September 30, 2023, March 31, 2024 and June 30, 2024. The Notice from Nasdaq is standard practice in the event of a delayed periodic financial report filing and was anticipated.
2024年11月12日，公司曾宣佈，由於需要重新審計截至2023年和2022年12月31日的經審計合併基本報表及截至2023年12月31日的三年期間的每個季度和年度（如適用）未審計合併基本報表的提交，將會延遲提交10-Q表。來自納斯達克的通知在定期基本報表提交延遲時是標準做法，並且是預期之中的。
The Company is continuing to work expeditiously to complete the filing of the Form 10-Q and remains on track to complete the restatement and all required filings by the end of 2024.
本公司正在加快工作以完成10-Q表的提交，並仍在計劃於2024年底之前完成重新審計和所有必需的提交。
This announcement is made in compliance with Nasdaq Listing Rule 5250(b)(2).
本公告是爲了遵守納斯達克上市規則5250(b)(2)。
About Quanterix
關於Quanterix
From discovery to diagnostics, Quanterix's ultrasensitive biomarker detection is fueling breakthroughs only made possible through its unparalleled sensitivity and flexibility. The Company's Simoa technology has delivered the gold standard for earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the Level of Quantification (LoQ). Its industry-leading precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Quanterix has been a trusted partner of the scientific community for nearly two decades, powering research published in more than 3,100 peer-reviewed journals. Find additional information about the Billerica, Massachusetts-based company at or follow us on Twitter and LinkedIn.
從發現到診斷，Quanterix的超靈敏生物標誌物檢測推動了只有通過其無與倫比的靈敏度和靈活性才能實現的突破。公司的Simoa技術提供了血液、血清或血漿中更早的生物標誌物檢測的黃金標準，具有定量遠低於定量限（LoQ）蛋白質的能力。其行業領先的精密設備、數字免疫測定技術和CLIA認證的加速實驗室支持研究，從而推進神經學、腫瘤學、免疫學、心臟病學和傳染病中的疾病理解和管理。Quanterix在近二十年來一直是科學社區值得信賴的合作伙伴，推動着在3100多本同行評審期刊上發表的研究。有關總部位於馬薩諸塞州比勒裏卡的公司的其他信息，請訪問或在Twitter和LinkedIn上關注我們。
Forward-Looking Statements
前瞻性聲明
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this press release are based on Quanterix's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix's actual results to differ from those expressed or implied in the forward-looking statements in this press release include, but are not limited to, that the Company may have underestimated the scope and impact of the restatement of certain of its financial statement and the risk that the Company's restated financial statements may take longer to complete than expected, as well as those described in our periodic reports filed with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
本新聞稿包含1995年《私募證券訴訟改革法案》意義下的前瞻性聲明。諸如「可能」、「將」、「期望」、「計劃」、「預期」、「估計」、「打算」等詞彙，以及其他與未來事件、條件或情況相關的詞語或表達，旨在識別前瞻性聲明。本新聞稿中的前瞻性聲明基於Quanterix截至本新聞稿日期的期望和假設。每一項前瞻性聲明都涉及風險和不確定性。可能導致Quanterix的實際結果與本新聞稿中前瞻性聲明所表達或暗示的結果不同的因素包括但不限於，公司可能低估了對其財務報表重新表述的範圍和影響，以及公司的重新表述財務報表完成所需時間可能超出預期的風險，以及在我們向美國證券交易委員會提交的定期報告中所描述的那些因素，包括其中包含的「風險因素」部分。除法律要求外，Quanterix不承擔更新任何此處包含的前瞻性聲明的義務，以反映期望的任何變化，即使在新信息可用時。
View source version on businesswire.com:
在businesswire.com查看源版本：
Media:
media@quanterix.com
媒體：
media@Quanterix.com
Investor Relations:
Amy Achorn
(978) 488-1854
ir@quanterix.com
投資者關係：
艾米·阿科恩
(978) 488-1854
ir@Quanterix.com
Source: Quanterix Corporation
來源：Quanterix公司